Table 7.
Association of HSP90AB1 gene polymorphisms with efficacy of glucocorticoids in SLE patients
| Models | Insensitive (n = 186) | Sensitive (n = 271) | Crude OR (95%CI) | P | Adjusted OR (95%CI) | P adj | P BH | |
|---|---|---|---|---|---|---|---|---|
| rs9367190 | ||||||||
| Dominant | CC | 99 (53.23) | 136 (50.18) | 0.885 (0.609‐1.286) | 0.523 | 0.907 (0.617‐1.335) | 0.622 | 0.889 |
| CA + AA | 87 (46.77) | 135 (49.82) | ||||||
| Recessive | CC + CA | 178 (95.70) | 251 (92.62) | 0.564 (0.243‐1.309) | 0.183 | 0.539 (0.227‐1.279) | 0.161 | 0.889 |
| AA | 8 (4.30) | 20 (7.38) | ||||||
| Additive | CC | 99 (53.23) | 136 (50.18) | 0.847 (0.621‐1.154) | 0.291 | 0.855 (0.622‐1.176) | 0.335 | 0.889 |
| CA | 79 (42.47) | 115 (42.44) | ||||||
| AA | 8 (4.30) | 20 (7.38) | ||||||
| Allele | C | 277 (74.46) | 387 (71.40) | 0.856 (0.635‐1.154) | 0.308 | — | — | — |
| A | 95 (25.54) | 155 (28.60) | ||||||
| rs13296 | ||||||||
| Dominant | GG | 74 (39.78) | 111 (40.96) | 1.050 (0.718‐1.536) | 0.802 | 1.028 (0.696‐1.518) | 0.889 | 0.889 |
| GA + AA | 112 (60.22) | 160 (59.04) | ||||||
| Recessive | GG + GA | 161 (86.56) | 239 (88.19) | 1.160 (0.662‐2.030) | 0.604 | 1.052 (0.592‐1.868) | 0.864 | 0.889 |
| AA | 25 (13.44) | 32 (11.81) | ||||||
| Additive | GG | 74 (39.79) | 111 (40.96) | 1.064 (0.806‐1.405) | 0.661 | 1.027 (0.774‐1.364) | 0.852 | 0.889 |
| GA | 87 (46.77) | 128 (47.23) | ||||||
| AA | 25 (13.44) | 32 (11.81) | ||||||
| Allele | G | 235 (63.17) | 350 (64.58) | 1.063 (0.808‐1.398) | 0.664 | — | — | — |
| A | 137 (36.83) | 192 (35.42) | ||||||
Abbreviations: CI, confidence intervals; OR, odds ratio; P adj, Adjusted by age, gender, BMI, marital status, smoking, drinking, drinking tea, GCs exposure before inclusion, baseline SLEDAI scores and GCs therapeutic dose; P BH, P value of Benjamini‐Hochberg method for false discovery rate.